Data from EMC - Curated by EPG Health - Last updated 23 August 2016

Indication(s)


- Premarin 0.3 mg Coated Tablets:

Hormone replacement therapy for estrogen deficiency symptoms in postmenopausal women.



- Premarin 0.625 mg Coated Tablets / Premarin 1.25 mg Coated Tablets:

− Hormone replacement therapy for estrogen deficiency symptoms in postmenopausal women.

− Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis.

 

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Cushing's Syndrome

Cushing's Syndrome

Cushing’s syndrome shares symptoms such as hypertension, glucose intolerance and obesity with other common conditions – how can you confidently diagnose this rare disorder?

+ 2 more

Cardiovascular Metabolism Knowledge Centre

Cardiovascular Metabolism Knowledge Centre

The Cardiovascular Metabolism Knowledge Centre is an information hub providing expert insight into the management of hypertension and type 2 diabetes. This Knowledge Centre contains a wealth of scientific video content offering insights and opinion from some of the leading experts in the field.

Fluid Management

Fluid Management

Are you up-to-date with the latest evidence of effective procedures for fluid management?

+ 2 more

Load more

Related Content

Journal articles

Efficacy of zoledronic acid in treatment of osteoporosis in men and women-a meta-analysis.

Background: Osteoporosis is a significant cause of morbidity and mortality in the elderly and an important public health issue. Bisphosphonates...

Added 4 years ago

Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.

Background: Romosozumab is a monoclonal antibody that binds to and inhibits sclerostin, increases bone formation, and decreases bone resorption.

Added 1 year ago

Effects of strontium ranelate on markers of cardiovascular risk in postmenopausal osteoporotic women.

Recent pooled analyses have shown that strontium ranelate increases the incidence of venous thromboembolism and non-fatal myocardial infarction, but no...

Added 3 years ago

Load more

View all 13535 Journal articles items
Guidelines

Management of osteoporosis and the prevention of fragility fractures

This guideline provides recommendations based on current evidence for best practice in the management of osteoporosis and prevention of fractures.

Added 4 years ago

Menopause: diagnosis and management

This guideline covers the diagnosis and management of menopause, including in women who have premature ovarian insufficiency. The guideline aims to improve the consistency of support and information provided to women in menopause.

Added 3 years ago

Bone health in cancer patients: ESMO Clinical Practice Guidelines

This new ESMO guideline covers areas that make bone health in cancer patients of increasing clinical importance. Besides describing incidence, epidemiology and clinical consequences of bone metastases...

Added 5 years ago

Load more

View all 1465 Guidelines items

More information

Category Value
Orphan designation No
Type POM
Marketing authorisation holder Pfizer Limited